

Title Complete pathologic response rectal cancers EYSAC.1 Study
Acronym CORSiCA

Name of the Principal Investigator. Lorenzon Laura

Name of the PI's Host Institution for the project. *Sapienza* University

Name of Project Partner. European Society of Surgical Oncology - ESSO

Proposal duration. 60 months

Proposal Summary

Background. About 20% of rectal cancers who underwent neoadjuvant treatment (neoCHT-RT) achieve a pathological complete response in the surgical specimen (ypT0); however, about 10% of ypT0 present metastatic nodes (N+). ypTON+ identification could be crucial in order to tailor treatments.

Aim 1. To create a large European Database (DB) of ypT0.

Aim 2. To compare ypTON0 vs ypTON+ with respect of their clinical/radiological/molecular features.

Aim 3. To investigate long term results.

Preliminary Study. Dr Lorenzon is the PI of an Italian retrospective multicentric study conducted on 230 ypT0 focused on treatment and outcomes.

Design. The PI will operate at *Sapienza* University in partnership with the European Society of Surgical Oncology (ESSO). An on-line DB using electronic data capture and Cloud technology will be used by ESSO-affiliated centres for collecting the clinical, pathological and radiological data of ypTON0/N+, previously treated (last 5 years) and prospectively enrolled (3 years + 2 years of follow-up). ypTON0 and ypTON+ will be compared for the clinical/pathological variables, for the gene expression profiles of pre-neoCHT-RT biopsies (NanoString nCounter Platform) and for the differences in MRI and PET scans (obtained before and after neoCHT-RT). Uni-multivariate survival analyses (end-points: OS, DFS, DSS) will be conducted at 3 and 5 years of follow-up.

Synopsis

Prospectus. The **COmplete pathologic ReSponse rectal Cancers EYSAC.1 Study (CORSiCA)** proposed by Dr Lorenzon will be conducted at *Sapienza* University of Rome in partnership with the European Society of Surgical Oncology (ESSO) – Young Alumni Club, and it will focus on rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (**pathologic complete response, pCR - ypT0**).

Rectal Cancer and Pathologic Complete Response. With about 135.000 new European (EU) cases¹⁻² each year, rectal cancer is a major European issue representing also a field of major investigations. Indeed, over the last 3 decades important advances have been made in the clinical/surgical management of these patients: the most significant ones were the introduction of total mesorectal excision (TME)³⁻⁴ and the use of neo-adjuvant (chemo)radiation treatments (neoCHT-RT)⁵⁻⁹ which changed dramatically the state of art and the multimodal approach to this disease. Currently, the latest international guidelines recommend performing a neoCHT-RT in locally advanced, non-metastatic rectal cancers, clinically staged as $\geq T3$ any N, any T N+ or if the circumferential resection margin (CRM) is less than 1 mm, since this approach results in less local recurrences, tumor down-sizing and down-staging¹⁰⁻¹¹. In line with all the improvements made so far, the ultimate effect of neoCHT-RT is the achievement of a complete response, which may be defined as clinical (absence of residual primary tumor clinically detectable, cT0) or pathological. ypT0 occurs in about 20% of patients who underwent neoCHT-RT¹²⁻¹³. Of note, neoadjuvant treatment modalities include a short-course radiotherapy (short RT) followed by immediate surgery or a long course chemo-radiotherapy (CHT-RT) followed by surgery delayed after an interval of at least 4 weeks¹⁰.

Literature and ypT0. Literature about complete responders is quite recent and started to emerge just over the last 15 years. Although very few large retrospective studies¹³⁻¹⁷ or systematic reviews/meta-analyses¹⁸⁻²⁰ have been published so far, results are still at an early stage, mostly because there are no robust markers predictive of pCR (molecular, clinical or radiological)¹⁹⁻²⁰, a number of surgical approaches have been considered (from local excisions to abdominoperianal resection)¹⁴ and there is no *consensus* regarding the adjuvant treatment following surgical resection¹⁶. However, the management of response following neoCHT-RT is the challenge of our times.

ypT0 N+ Rectal Cancers. A key issue in relation to pCR, is the presence of residual cancerous cells within lymph-nodes harvested in the surgical specimen (ypTON+). These patients account for the 6.7-17.4%^{13;21} of ypT0 and are seldom analyzed, since the vast majority of studies in this field has been conducted pooling together ypT0-ypT2 patients²¹⁻²²; accordingly, a large analysis based exclusively on the ypT0 subgroup is still missing. Nevertheless, literature published so far documented that a clinical nodal positivity before neoCHT-RT has been correlated with nodal metastases²¹⁻²³. An accurate prediction of the nodal *status*, however, would be crucial in order to tailor surgical choices.

Aims

- ✓ **Specific Aim 1.** To create a large European Database of ypT0 patients from multiple institutions by involvement of young researchers (short-term aim)
- ✓ **Specific Aim 2.** To compare ypTON0 vs ypTON+ patients with respect of their clinical, radiological and molecular features (mid-term aim)
- ✓ **Specific Aim 3.** To define pattern and timing of relapses and to conduct a multivariate analysis of survivals which would include the N *status* and the use of adjuvant treatment (long-term aim)


Methods

Aim 1. Clinical data will be acquired using an on-line Database (DB) based on electronic data capture and Cloud technology, as successfully applied by recent large multicenter trials.

Aim 2. Patients presenting nodal positivity on TME specimens will be compared to the nodal negative patients for statistical purpose. Comparison will aim to define clinical, radiological and molecular features.

Aim 3. ypTON0 patients and ypTON+ patients will be compared with the end-points of overall survival (OS, any cause of death), disease free survival (DFS, first recurrence after surgical resection) and disease specific survival (DSS, death related to colorectal cancer) at 3 years and 5 years of follow up.

Figure 1. Study Design - Overview



References

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent *et al.* Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013; **49**: 1374-1403.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; **66**: 7-30.
3. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet* 1986; **1**: 1479-1482.
4. Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. *Br J Surg* 2002; **89**: 1142-1149.
5. van Gijn W, Marijnen CA, Nagtegaal ID *et al.* Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol* 2011; **12**: 575-582.
6. Bujko K, Nowacki MP, Nasierowska-Guttmejer A *et al.* Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg* 2006; **93**: 1215-1223.
7. Gerard JP, Conroy T, Bonnetain F *et al.* Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. *J Clin Oncol* 2006; **24**: 4620-4625.
8. Sauer R, Liersch T, Merkel S *et al.* Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol* 2012; **30**: 1926-1933.
9. Bosset JF, Calais G, Mineur L *et al.* Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. *Lancet Oncol* 2014; **15**: 184-190.
10. Schmoll HJ, Van Cutsem E, Stein A *et al.* ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. *Ann Oncol* 2012; **23**: 2479-2516.
11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Version 2.2016; 04.06.2016; www.nccn.org
12. Habr-Gama A, Perez RO, Nadalin W *et al.* Operative versus non operative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg* 2004; **240**: 711-717.
13. Al-Sukhni E, Attwood K, Mattson DM *et al.* Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. *Ann Surg Oncol* 2016; **23**: 1177-1186.

14. Capirci C, Valentini V, Cionini L *et al.* Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. *Int J Radiat Oncol Biol Phys* 2008; **72**: 99-107.
15. Maas M, Nelemans PJ, Valentini V *et al.* Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. *Lancet Oncol* 2010; **11**: 835-844.
16. Maas M, Nelemans PJ, Valentini V *et al.* Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. *Int J Cancer* 2015; **137**: 212-220.
17. Probst CP, Becerra AZ, Aquina CT *et al.* Extended Intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. *J Am Coll Surg* 2015; **221**: 430-440.
18. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. *Br J Surg* 2012; **99**: 918-928.
19. Ryan JE, Warriar SK, Lynch AC *et al.* Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. *Colorectal Dis* 2015; **17**: 849-861.
20. Ryan JE, Warriar SK, Lynch AC *et al.* Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. *Colorectal Dis* 2016; **18**: 234-246.
21. Bosch SL, Vermeer TA, West NP *et al.* Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy. *Histopathology* 2016 Jun 6. doi: 10.1111/his.13008.
22. Park IJ, You YN, Skibber JM *et al.* Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. *Dis Colon Rectum* 2013; **56**: 135-141.
23. Wan J, Liu K, Zhu J *et al.* Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation. *Oncotarget* 2015; **6**: 11714-11722.